<DOC>
	<DOCNO>NCT01238952</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate dose/recommended phase II dose combination regimen NK012 carboplatin patient advance solid tumor .</brief_summary>
	<brief_title>Study NK012 Carboplatin Solid Tumors With Dose Expansion Triple Negative Breast Cancer</brief_title>
	<detailed_description>NK012 administer 30 minute IV infusion , follow 30 minute carboplatin IV infusion . Both drug administer every 28 day . Treatment expect continue 6 cycle , unless disease progression development unacceptable toxicity require discontinuation drug . At discretion investigator , patient show sign benefit may continue beyond 6 cycle . Once MTD/RD determine , dose expansion cohort patient metastatic triple negative breast cancer treat determined MTD .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis advance solid tumor efficacious therapy exists , camptothecinbased regimen would appropriate . 2 . For dose expansion MTD/RD : 1 . Patients must triplenegative breast cancer locally advanced disease surgical option , stage IV disease . Triplenegative breast cancer define HER2negative , ERnegative , PRnegative follow : For HER2 negative ( must meet one follow 3 ) : ( ) FISH negative ( ratio &lt; 2.2 ) ; ( ii ) IHC 0 1+ ; ( iii ) IHC 2+ 3+ FISH negative ( ratio &lt; 2.2 ) For ER negative PR negative : ≤ 10 % tumor stain IHC 2 . No less one two prior chemotherapy regimen advance metastatic breast cancer . 3 . Patients must measurable disease RECIST ( version 1.1 ) . 3 . Patients must recover acute adverse effect prior therapy , exclude alopecia . 4 . For patient enrol dose escalation phase , 4 prior cytotoxic regimen metastatic setting . 5 . Prior irradiation 25 % bone marrow . 6 . ECOG performance status 0 1 . 7 . Life expectancy least 12 week . 8 . Patients least 18 year age . 9 . Adequate bone marrow function define ANC ≥ 1500/mm^3 platelet count ≥ 100,000/mm^3 . 10 . AST ALT ≤ 3.0 x ULN ( 5X ULN document liver metastasis ) total bilirubin ≤ 1.5 x ULN . 11 . Serum creatinine &lt; 1.5 x ULN , creatinine clearance &gt; 60 mL/min CockcroftGault formula* patient serum creatinine &gt; 1.5x ULN . * CockcroftGault formula creatinine clearance ( CrCl ) : Males : CrCl ( ml/min ) = ( 140 age ) x wt ( kg ) / ( serum creatinine x 72 ) Females : Multiply result 0.85 12 . Able understand show willingness sign write informed consent document . 1 . Prior chemotherapy , radiation therapy , investigational therapy within 4 week ( exception : 6 week nitrosoureas mitomycin C ) ; prior noncytotoxic therapy within 5 drug halflives ( 4 week , ever short ) ; monoclonal antibody within 4 week prior first dose study treatment . 2 . Concurrent use another investigational agent . 3 . History brain metastasis spinal cord compression , unless irradiate treat minimum 4 week prior first study treatment stable without requirement corticosteroid &gt; 1 week . 4 . Concurrent serious infection require parenteral antibiotic therapy . 5 . Pregnant childbearing potential use method avoid pregnancy . A negative pregnancy test must document baseline woman childbearing potential . Patients may breast feed infant study . 6 . Significant cardiac disease include heart failure meet NYHA class III IV definition , history myocardial infarction within 6 month study entry , uncontrolled dysrhythmias poorly control angina . 7 . History serious ventricular arrhythmia ( VT VF , ≥ 3 beat row ) , QTc ≥ 450 msec men 470 msec woman , LVEF ≤ 40 % MUGA ECHO . 8 . History allergic reaction attribute compound topoisomerase I inhibitor , platinumcontaining compound . 9 . Prior treatment irinotecan . 10 . Prior treatment 6 cycle platinum drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>breast cancer</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>ER negative</keyword>
	<keyword>PR negative</keyword>
</DOC>